论文部分内容阅读
目的观察低分子肝素钠联合尿激酶在缺血性脑卒中的疗效。方法新发1周内脑血栓形成脑梗死患者80例随机均分成两组:对照组给予常规治疗;观察组加用低分子肝素钠和小剂量尿激酶治疗。比较两组疗效和不良反应发生率。结果观察组治疗有效率82.5%,明显高于对照组的57.5%(P<0.05);观察组治疗后神经功能缺损评分(11.3±3.6)分,明显优于治疗前的(16.4±4.2)分和对照组治疗后的(18.5±5.0)分(P<0.05)。两组不良反应发生率情况相仿(7.5%vs.10.0%)(P>0.05)。结论低分子肝素钠联合小剂量尿激酶在脑血栓形成的治疗中临床疗效好,无明显不良反应发生。
Objective To observe the effect of low molecular weight heparin combined with urokinase in ischemic stroke. Methods One week after the new onset of cerebral thrombosis, 80 patients with cerebral infarction were randomly divided into two groups: the control group given routine treatment; the observation group plus low molecular weight heparin and low-dose urokinase treatment. The curative effect and incidence of adverse reactions in both groups were compared. Results The effective rate of observation group was 82.5%, which was significantly higher than that of control group (57.5%, P <0.05). The score of neurological deficit (11.3 ± 3.6) in observation group was significantly better than that before treatment (16.4 ± 4.2) And (18.5 ± 5.0) points after treatment in the control group (P <0.05). The incidence of adverse reactions in both groups was similar (7.5% vs. 10.0%) (P> 0.05). Conclusion Low molecular weight heparin combined with low-dose urokinase has good clinical efficacy in the treatment of cerebral thrombosis, no obvious adverse reactions.